The efficacy of L- glutamine in sickle cell and sickell thalassemia

The efficacy of L- glutamine in the control of crisis event in patients with sickle cell and sickell thalassemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180603039959N1

Enrollment

Registered

2020-01-10

Start date

2018-06-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell and sickell thalassemia. Sickle-cell disorders

Interventions

15 patient with sickle cell and sickell thalassemia that have slection criteria were selected.In this study, an outpatient patient will receive a L-glutamine of 10 to 30 grams per day, and rate of cr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with sickle cell and sickell thalassemia

Exclusion criteria

Exclusion criteria: Kidney impairment Renal impaiment HB <5 gr Need to emergency transfusion Pregnancy Admition more than 10 times Sensivity to glutamin

Design outcomes

Primary

Measure	Time frame
Effect to crisis event. Timepoint: at the end of fourth and eighth week. Method of measurement: pain-admition times-crisis.	—

Secondary

Measure	Time frame
Crisis event. Timepoint: at the end of fourth and eight weeks. Method of measurement: Face Pain Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Farmani Anooshe

Ahvaz University of Medical Sciences

nedafarmanianoosheh@gmail.com+98 41 3336 1658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026